Self-Injections Market Report 2025

The self-injections market size has grown strongly in recent years. It will grow from $9.69 billion in 2024 to $10.3 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to rising chronic diseases, improved patient empowerment, regulatory support, preference for home healthcare, cost-effectiveness.

The self-injections market size is expected to see strong growth in the next few years. It will grow to $14.13 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to pandemic impact and remote treatment, expansion into emerging markets, patient-centric healthcare, advantages in drug delivery, personalized medicine trends. Major trends in the forecast period include smart technology integration, rise in biologics usage, miniaturization and wearable devices, enhanced safety features, adoption of autoinjectors.

The increasing number of diabetic patients is anticipated to drive the growth of the self-injections market in the future. Diabetes is a condition where the pancreas, an organ responsible for producing insulin, generates an insufficient amount of insulin, leading to the breakdown of blood sugar and resulting in severe health conditions such as heart disease, vision loss, and kidney disease. Self-injections allow diabetic patients to administer insulin and other medications themselves, helping to regulate blood sugar levels and prevent excess sugar without the need for assistance from a medical professional. For example, according to the IDF Diabetes Atlas, a Belgium-based global resource offering comprehensive data on diabetes prevalence, treatment, and care, the global number of diabetes cases is expected to rise from 643 million in 2030 to 783 million by 2045, an increase of 140 million cases. Currently, 537 million adults live with diabetes, with more than 75% residing in low- and middle-income countries. Therefore, the growing number of diabetic patients is significantly contributing to the expansion of the self-injections market.

The rise of telehealth and telemedicine is expected to drive the growth of the self-injections market in the future. Telehealth involves the use of telecommunications technology to deliver a wide range of healthcare services and information remotely, while telemedicine focuses specifically on remote clinical consultations and healthcare delivery. These digital health platforms enable virtual consultations, allowing healthcare providers to prescribe self-injectable medications from a distance. Patients also benefit from virtual training sessions that ensure they administer self-injections correctly. Additionally, telehealth facilitates real-time monitoring of patient adherence, ongoing disease management, and easy access to telepharmacy services for medication delivery. The convenience of telehealth, especially during pandemics, enhances patient engagement and improves overall access to specialized care, significantly contributing to the growth of the self-injections market. For example, according to Telehealth.HHS.gov, a U.S. government information provider, telehealth usage reached approximately 21,883,731 users in Q4 2023, marking an increase of 2,783,159 users, or 13%, compared to the previous quarter. Thus, the increase in telehealth and telemedicine is driving the expansion of the self-injections market.

Innovation in insulin injection solutions is a key trend in the self-injections market, with major companies focusing on developing new products to gain a competitive edge. For example, in September 2022, Terumo Corporation, a Japan-based medical device company, launched FineGlide, a sterile pen needle designed for patients requiring regular insulin injections or other self-medication. FineGlide prioritizes patient comfort by featuring a 3-bevel super sharp needle with a high-grade silicone surface, ensuring gentleness during injections. The inclusion of Thin Wall Technology improves flow rate and reduces injection force, enhancing the overall experience for patients and promoting drug compliance. This focus on product innovation demonstrates the commitment of major companies to meet the evolving needs of patients in the self-injections market.

Major players in the self-injections market are focusing on the development of smart injecting devices to gain a competitive advantage. In March 2022, Pfizer Inc., a prominent US-based pharmaceutical company, introduced ENBREL SmartClic in Australia. This innovative self-injecting device is designed for patients undergoing treatment with ENBREL, a tumor necrosis factor (TNF) inhibitor prescribed for conditions like Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), and Psoriatic Arthritis (PsA). ENBREL SmartClic features an automated, reusable design with user-friendly elements, including a one-button initiation, a larger grip compared to the Enbrel Auto-Injector, and injection speed control. The device is accompanied by a smartphone app, providing additional features such as reminders, injection history recording, site tracking, and streamlined reports. Patients can access these features on their smartphones and share the information with healthcare professionals, enhancing the overall self-injection experience for those dealing with chronic inflammatory diseases.

In June 2022, Dr. Reddy Labs, an India-based pharmaceutical manufacturer, made a significant acquisition by purchasing an injectable portfolio from Eton Pharma for $50 million. This strategic move by Dr. Reddy's aimed to accelerate and expand the availability of affordable medications for patients. The acquisition included new portfolios such as injections and recipes, allowing Dr. Reddy's to diversify its product offerings and strengthen its position in the pharmaceutical market. Eton Pharma, a US-based pharmaceutical manufacturer, contributed to Dr. Reddy's efforts to broaden its pharmaceutical portfolio, signaling a strategic expansion into injectable medications.

Major companies operating in the self-injections market are AbbVie Inc., Antares Pharma Inc., Baxter International Inc., Bayer AG, Becton Dickinson and Company, Bristol-Myers Squibb Company, Credence MedSystems Inc., Dali Medical Devices Ltd., Eli Lilly and Company, Enable Injections Inc., Gerresheimer AG, Insulet Corporation, Merck & Co. Inc., Owen Mumford Limited, Pfizer Inc., PharmaJet Inc., Recipharm AB, Schott AG, SHL Group Limited, Terumo Corporation, West Pharmaceutical Services Inc., Wilhelm Haselmeier GmbH & Co. KG, Ypsomed Holding AG, APTAR PHARMA INDIA PVT LTD, Bespak Europe Ltd., Bioject Medical Technologies Inc., Catalent Inc., Crossject SA, Injex Pharma AG, Medeca Pharma AB, Medimop Medical Projects Ltd., Mylan N.V., Nemera Development S.A., Noble Medical Inc.

North America was the largest region in the self injections market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the self-injections market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the self-injections market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Self-injection refers to the act of administering medications or drugs through a device by an individual to themselves without the assistance of a medical professional. This practice allows patients to independently manage their medication regimen.

The primary types of self-injections encompass devices and formulations. These devices enable patients to self-administer medications that require injection without relying on medical professionals. Self-injection devices are utilized for various routes of administration such as skin, circulatory or musculoskeletal systems, organs, and the central nervous system. Dosage types include single-dose and multi-dose, catering to applications in autoimmune diseases, hormonal disorders, oncology, orphan diseases, pain management, respiratory therapy, among others. These devices are distributed through various channels including hospitals, pharmacies, clinics, chemists, and online pharmacies.

The self injections market research report is one of a series of new reports that provides self injections market statistics, including self injections industry global market size, regional shares, competitors with a self injections market share, detailed self injections market segments, market trends and opportunities, and any further data you may need to thrive in the self injections industry. This self injections market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The self injections market consists of sales of auto-injectors, needle-free injectors, pen injectors and wearable injectors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.